Processing

Please wait...

Settings

Settings

Goto Application

1. EP1294904 - HETERODIMERIC FUSION PROTEINS

Office
European Patent Office
Application Number 01949457
Application Date 29.06.2001
Publication Number 1294904
Publication Date 26.03.2003
Publication Kind A1
IPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
CPC
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/468
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
C07K 2317/626
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
626Diabody or triabody
C07K 2317/64
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
64comprising a combination of variable region and constant region components
Applicants VLAAMS INTERUNIV INST BIOTECH
Inventors MERTENS NICO
GROOTEN JOHAN
Designated States
Priority Data 00202306 30.06.2000 EP
0107557 29.06.2001 EP
01949457 29.06.2001 EP
Title
(DE) HETERODIMÄRE FUSIONSPROTEINE
(EN) HETERODIMERIC FUSION PROTEINS
(FR) PROTEINES DE FUSION HETERODIMERES
Abstract
(EN)
The present invention relates to the production of bispecific or multispecific, bi- or tetravalent antibodies using recombinant DNA methods and recombinant production methods. The resulting antibody consists of one or two diabody molecules that are heterodimerized by creating a fusion protein with the CL and CH1 immunoglobulin constant domains.

(FR)
La présente invention concerne la production d'anticorps bispécifiques ou multispécifiques, bi- ou tétravalents, par des techniques de recombinaison d'ADN et des techniques de production de recombinés. L'anticorps obtenu est constitué d'une ou de deux molécules de dianticorps qui subissent une hétérodimérisation via la création d'une protéine de fusion avec les domaines constants d'immunoglobuline CL et CH1.